325 related articles for article (PubMed ID: 38540438)
1. Pediatric Beta Blocker Therapy: A Comprehensive Review of Development and Genetic Variation to Guide Precision-Based Therapy in Children, Adolescents, and Young Adults.
Walton M; Wagner JB
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540438
[TBL] [Abstract][Full Text] [Related]
2. National prescribing trends for heart failure medications in children.
Moffett BS; Price JF
Congenit Heart Dis; 2015; 10(1):78-85. PubMed ID: 24725766
[TBL] [Abstract][Full Text] [Related]
3. Trends in the off-label use of β-blockers in pediatric patients.
Kaley VR; Aregullin EO; Samuel BP; Vettukattil JJ
Pediatr Int; 2019 Nov; 61(11):1071-1080. PubMed ID: 31571355
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics for Drug Dosing in Children: Current Use, Knowledge, and Gaps.
Hoshitsuki K; Fernandez CA; Yang JJ
J Clin Pharmacol; 2021 Jun; 61 Suppl 1(Suppl 1):S188-S192. PubMed ID: 34185912
[TBL] [Abstract][Full Text] [Related]
5. Beta-blockers for congestive heart failure in children.
Alabed S; Sabouni A; Al Dakhoul S; Bdaiwi Y
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD007037. PubMed ID: 32700759
[TBL] [Abstract][Full Text] [Related]
6. Beta-blockers for congestive heart failure in children.
Alabed S; Sabouni A; Al Dakhoul S; Bdaiwi Y; Frobel-Mercier AK
Cochrane Database Syst Rev; 2016 Jan; (1):CD007037. PubMed ID: 26820557
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic factors affecting β-blocker metabolism and response.
Thomas CD; Johnson JA
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):953-964. PubMed ID: 32726152
[TBL] [Abstract][Full Text] [Related]
9. Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure?
Bruns LA; Canter CE
Paediatr Drugs; 2002; 4(12):771-8. PubMed ID: 12431129
[TBL] [Abstract][Full Text] [Related]
10. Trends in off-label beta-blocker use: a secondary data analysis.
Lin HW; Phan K; Lin SJ
Clin Ther; 2006 Oct; 28(10):1736-46; discussion 1710-1. PubMed ID: 17157130
[TBL] [Abstract][Full Text] [Related]
11. Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children.
Wagner J; Leeder JS
Pediatr Clin North Am; 2012 Oct; 59(5):1017-37. PubMed ID: 23036242
[TBL] [Abstract][Full Text] [Related]
12. Establishing Baseline Metrics of Heart Failure Medication Use in Children: A Collaborative Effort from the ACTION Network.
Stidham J; Feingold B; Almond CS; Burstein DS; Krack P; Price JF; Schumacher KR; Spinner JA; Rosenthal DN; Lorts A; Godown J
Pediatr Cardiol; 2021 Feb; 42(2):315-323. PubMed ID: 33044586
[TBL] [Abstract][Full Text] [Related]
13. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project.
Krumholz HM; Radford MJ; Wang Y; Chen J; Heiat A; Marciniak TA
JAMA; 1998 Aug; 280(7):623-9. PubMed ID: 9718054
[TBL] [Abstract][Full Text] [Related]
14. Beta-Blockers for Exams Identify Students at High Risk of Psychiatric Morbidity.
Butt JH; Dalsgaard S; Torp-Pedersen C; Køber L; Gislason GH; Kruuse C; Fosbøl EL
J Child Adolesc Psychopharmacol; 2017 Apr; 27(3):266-273. PubMed ID: 27782771
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
Gambarin FI; Favalli V; Serio A; Regazzi M; Pasotti M; Klersy C; Dore R; Mannarino S; Viganò M; Odero A; Amato S; Tavazzi L; Arbustini E
J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):354-62. PubMed ID: 19430350
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic treatment of chronic pediatric hypertension.
Robinson RF; Nahata MC; Batisky DL; Mahan JD
Paediatr Drugs; 2005; 7(1):27-40. PubMed ID: 15777109
[TBL] [Abstract][Full Text] [Related]
17. Drug Use Evaluation of Beta-Blockers in Medical Wards of Nedjo General Hospital, Western Ethiopia.
Fekadu G; Bekele F; Bekele K; Hanbisa S; Belay G; Maqbool M
Cardiovasc Ther; 2020; 2020():2509875. PubMed ID: 32565908
[TBL] [Abstract][Full Text] [Related]
18. Neurocardiogenic syncope in children : current concepts in diagnosis and management.
Massin M
Paediatr Drugs; 2003; 5(5):327-34. PubMed ID: 12716219
[TBL] [Abstract][Full Text] [Related]
19. Current Practices in Pharmacogenomics.
Ramsey LB; Prows CA; Tang Girdwood S; Van Driest S
Pediatr Clin North Am; 2023 Oct; 70(5):995-1011. PubMed ID: 37704356
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension.
Chen JM; Heran BS; Perez MI; Wright JM
Cochrane Database Syst Rev; 2010 Jan; (1):CD007185. PubMed ID: 20091622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
